“
TL;DR
This study measured biomarkers of bone and cartilage turnover in alkaptonuria patients from the SONIA 2 trial. It found that nitisinone treatment altered the levels of biomarkers for collagen type I and type II remodelling over four years.
International Journal of Molecular Sciences · 9 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study measured biomarkers of bone and cartilage turnover in alkaptonuria patients from the SONIA 2 trial. It found that nitisinone treatment altered the levels of biomarkers for collagen type I and type II remodelling over four years.
This observational analysis measured non-invasive biomarkers of bone (type I collagen) and cartilage (type II collagen) turnover in alkaptonuria patients from the SONIA 2 trial who received nitisinone. The study found a transient increase in bone resorption (CTX-I) and formation (PRO-C1) biomarkers after one year, followed by a return to baseline. For cartilage, the inflammatory-mediated marker C2M decreased markedly by Year 1, while the bone-associated cartilage marker CTX-II/Creat showed more pronounced reductions in younger and male patients. The study notes its limitation as having a relatively low number of patients for a rare disease, and that the four-year treatment duration may be insufficient to observe significant structural remodelling changes. The authors suggest these biomarkers could help identify patients for early treatment initiation and monitor long-term treatment effects on joint health.